Hatch-Waxman litigators are accustomed to cases with multiple generic drug company defendants. Brand drug company plaintiffs often sue multiple defendants in the same district court, even when those defendants are not...more
On April 4, 2017, in Novartis AG v. Noven Pharmaceuticals, Inc., the Federal Circuit affirmed the Patent Trial and Appeal Board’s (“PTAB’s”) holding that various claims of U.S. Patents 6,316,023 and 6,335,031 (“the Patents at...more